David A. Lewin, Ph.D., Since 2010 he has been an Sr. Associate Director of Licensing specializing in life sciences technology management and licensing with Yale University’s Office of Cooperative Research, which he joined in 2005. He is responsible for the intellectual property management, marketing, and licensing of a broad spectrum of technologies in the biological sciences arising from Yale laboratories. Such technologies range from pharmaceuticals to medical devices, microscope technology to diagnostic tests, platform technologies and the occasional software. His duties also include the management of alliances created in order to translate academic findings into commercial products and facilitating the founding of new ventures based to achieve such commercialization (Kolltan Pharmaceuticals, New Haven Pharmaceuticals, and Novatract Surgical, CanTx, BioHaven Pharmaceuticals). Prior to returning to Yale, where he did his thesis work in Cell Biology, Dr. Lewin was with CuraGen Corporation for seven years as Group Leader in Collaborative Research/Alliance Management. In this position he led CuraGen’s relationships with Genentech, Roche, Mitsubishi, Alexion, and other biotechnology companies and pharma. His duties at CuraGen included business development activities and he had ultimate responsibility for scientific deliverables to CuraGen’s alliance partners. As a Group Leader in Biomarkers for CuraGen, he discovered and developed clinical biomarkers for a protein drug in CuraGen’s pipeline that were implemented in clinical trials. Dr. Lewin’s undergraduate degree is from the University of California, San Diego, majoring in Cell Biology/Biochemistry, with minors in organic chemistry and literature.